{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "G2/M arrest",
      "PLK1",
      "RAD51",
      "TNBC",
      "chromothripsis"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "37793965",
  "DateCompleted": {
    "Year": "2024",
    "Month": "01",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2024",
    "Month": "01",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2023",
        "Month": "10",
        "Day": "02"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.trecan.2023.09.001",
      "S2405-8033(23)00173-5"
    ],
    "Journal": {
      "ISSN": "2405-8025",
      "JournalIssue": {
        "Volume": "10",
        "Issue": "1",
        "PubDate": {
          "Year": "2024",
          "Month": "Jan"
        }
      },
      "Title": "Trends in cancer",
      "ISOAbbreviation": "Trends Cancer"
    },
    "ArticleTitle": "CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response.",
    "Pagination": {
      "StartPage": "52",
      "EndPage": "64",
      "MedlinePgn": "52-64"
    },
    "Abstract": {
      "AbstractText": [
        "Human cancers share requirements for phosphorylation-dependent signaling, mitotic hyperactivity, and survival after DNA damage. The oncoprotein CIP2A (cancerous inhibitor of PP2A) can coordinate all these cancer cell characteristics. In addition to controlling cancer cell phosphoproteomes via inhibition of protein phosphatase PP2A, CIP2A directly interacts with the DNA damage protein TopBP1 (topoisomerase II-binding protein 1). Consequently, CIP2A allows DNA-damaged cells to enter mitosis and is essential for mitotic cells that are defective in homologous recombination (HR)-mediated DNA repair (e.g., BRCA mutants). The CIP2A-TopBP1 complex is also important for clustering fragmented chromosomes at mitosis. Clinically, CIP2A is a disease driver for basal-like triple-negative breast cancer (BL-TNBC) and a promising cancer therapy target across many cancer types."
      ],
      "CopyrightInformation": "Copyright \u00a9 2023 The Author(s). Published by Elsevier Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University, Turku, Finland; Institute of Biomedicine and FICANWest Cancer Center, University of Turku, Turku, Finland."
          }
        ],
        "LastName": "Nagelli",
        "ForeName": "Srikar",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University, Turku, Finland; Institute of Biomedicine and FICANWest Cancer Center, University of Turku, Turku, Finland; InFLAMES Research Flagship Center, University of Turku, Turku, Finland. Electronic address: jukwes@utu.fi."
          }
        ],
        "LastName": "Westermarck",
        "ForeName": "Jukka",
        "Initials": "J"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Trends Cancer",
    "NlmUniqueID": "101665956",
    "ISSNLinking": "2405-8025"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Intracellular Signaling Peptides and Proteins"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Intracellular Signaling Peptides and Proteins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Signal Transduction"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Mitosis"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "DNA Repair"
    }
  ],
  "CoiStatement": "Declaration of interests J.W. is a consultant and scientific advisory board member of Anavo Therapeutics B.V., and a founder and board member of Thestra Oy. S.N. declares no conflicts of interests."
}